Skip to main content
Erschienen in:

14.05.2018 | Epidemiology

Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database

verfasst von: Maryam Elmi, Arash Azin, Ahmad Elnahas, David R. McCready, Tulin D. Cil

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with genetic susceptibility to breast and ovarian cancer are eligible for risk-reduction surgery. Surgical morbidity of risk-reduction mastectomy (RRM) with concurrent bilateral salpingo-oophorectomy (BSO) is unknown. Outcomes in these patients were compared to patients undergoing RRM without BSO using a large multi-institutional database.

Methods

A retrospective cohort analysis was conducted using the American College of Surgeon’s National Surgical Quality Improvement Program (NSQIP) 2007–2016 datasets, comparing postoperative morbidity between patients undergoing RRM with patients undergoing RRM with concurrent BSO. Patients with genetic susceptibility to breast/ovarian cancer undergoing risk-reduction surgery were identified. The primary outcome was 30-day postoperative major morbidity. Secondary outcomes included surgical site infections, reoperations, readmissions, length of stay, and venous thromboembolic events. A multivariate analysis was performed to determine predictors of postoperative morbidity and the adjusted effect of concurrent BSO on morbidity.

Results

Of the 5470 patients undergoing RRM, 149 (2.7%) underwent concurrent BSO. The overall rate of major morbidity and postoperative infections was 4.5% and 4.6%, respectively. There was no significant difference in the rate of postoperative major morbidity (4.5% vs 4.7%, p = 0.91) or any of the secondary outcomes between patients undergoing RRM without BSO vs. those undergoing RRM with concurrent BSO. Multivariable analysis showed Body Mass Index (OR 1.05; p < 0.001) and smoking (OR 1.78; p = 0.003) to be the only predictors associated with major morbidity. Neither immediate breast reconstruction (OR 1.02; p = 0.93) nor concurrent BSO (OR 0.94; p = 0.89) were associated with increased postoperative major morbidity.

Conclusion

This study demonstrated that RRM with concurrent BSO was not associated with significant additional morbidity when compared to RRM without BSO. Therefore, this joint approach may be considered for select patients at risk for both breast and ovarian cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Kuchenbaecker KB et al (2017) Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Jama 317(23):2402–2416CrossRefPubMed Kuchenbaecker KB et al (2017) Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Jama 317(23):2402–2416CrossRefPubMed
3.
Zurück zum Zitat Mavaddat N et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812 – 22CrossRefPubMed Mavaddat N et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812 – 22CrossRefPubMed
4.
Zurück zum Zitat Meijers-Heijboer H et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345(3):159 – 64CrossRefPubMed Meijers-Heijboer H et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345(3):159 – 64CrossRefPubMed
5.
Zurück zum Zitat Rebbeck TR et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062CrossRefPubMed Rebbeck TR et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062CrossRefPubMed
6.
Zurück zum Zitat Hartmann LC et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340(2):77–84CrossRefPubMed Hartmann LC et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340(2):77–84CrossRefPubMed
7.
Zurück zum Zitat Ludwig KK et al (2016) Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg 212(4):660–669CrossRefPubMed Ludwig KK et al (2016) Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg 212(4):660–669CrossRefPubMed
8.
Zurück zum Zitat Gilbert M et al (2002) The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem 277(1):327 – 37CrossRefPubMed Gilbert M et al (2002) The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem 277(1):327 – 37CrossRefPubMed
9.
Zurück zum Zitat Domchek SM et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Jama 304(9):967 – 75CrossRefPubMedPubMedCentral Domchek SM et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Jama 304(9):967 – 75CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Rebbeck TR et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622CrossRefPubMed Rebbeck TR et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622CrossRefPubMed
11.
Zurück zum Zitat Kauff ND et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331–1337CrossRefPubMedPubMedCentral Kauff ND et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331–1337CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat J, S.C., et al., Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. Clin Breast Cancer, 2016. 16(6): 494–499 J, S.C., et al., Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. Clin Breast Cancer, 2016. 16(6): 494–499
13.
14.
Zurück zum Zitat Del Corral GA et al (2015) Outcomes and Cost Analysis in High-Risk Patients Undergoing Simultaneous Free Flap Breast Reconstruction and Gynecologic Procedures. Ann Plast Surg 75(5):534–538CrossRefPubMed Del Corral GA et al (2015) Outcomes and Cost Analysis in High-Risk Patients Undergoing Simultaneous Free Flap Breast Reconstruction and Gynecologic Procedures. Ann Plast Surg 75(5):534–538CrossRefPubMed
15.
Zurück zum Zitat Khadim MF et al (2013) Multidisciplinary one-stage risk-reducing gynaecological and breast surgery with immediate reconstruction in BRCA-gene carrier women. Eur J Surg Oncol 39(12):1346–1350CrossRefPubMed Khadim MF et al (2013) Multidisciplinary one-stage risk-reducing gynaecological and breast surgery with immediate reconstruction in BRCA-gene carrier women. Eur J Surg Oncol 39(12):1346–1350CrossRefPubMed
16.
Zurück zum Zitat Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80 – 7CrossRefPubMedPubMedCentral Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80 – 7CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15(1):21–33CrossRefPubMed Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15(1):21–33CrossRefPubMed
18.
Zurück zum Zitat Fischer JP et al (2013) Impact of obesity on outcomes in breast reconstruction: analysis of 15,937 patients from the ACS-NSQIP datasets. J Am Coll Surg 217(4):656 – 64CrossRefPubMed Fischer JP et al (2013) Impact of obesity on outcomes in breast reconstruction: analysis of 15,937 patients from the ACS-NSQIP datasets. J Am Coll Surg 217(4):656 – 64CrossRefPubMed
19.
Zurück zum Zitat Fischer JP et al (2014) Effect of BMI on modality-specific outcomes in immediate breast reconstruction (IBR)--a propensity-matched analysis using the 2005–2011 ACS-NSQIP datasets. J Plast Surg Hand Surg 48(5):297–304CrossRefPubMed Fischer JP et al (2014) Effect of BMI on modality-specific outcomes in immediate breast reconstruction (IBR)--a propensity-matched analysis using the 2005–2011 ACS-NSQIP datasets. J Plast Surg Hand Surg 48(5):297–304CrossRefPubMed
20.
Zurück zum Zitat Ilonzo N et al (2017) Breast reconstruction after mastectomy: A ten-year analysis of trends and immediate postoperative outcomes. Breast 32:7–12CrossRefPubMed Ilonzo N et al (2017) Breast reconstruction after mastectomy: A ten-year analysis of trends and immediate postoperative outcomes. Breast 32:7–12CrossRefPubMed
21.
Zurück zum Zitat Khoo A et al (1998) A comparison of resource costs of immediate and delayed breast reconstruction. Plast Reconstr Surg 101(4):964–968 discussion 969 – 70.CrossRefPubMed Khoo A et al (1998) A comparison of resource costs of immediate and delayed breast reconstruction. Plast Reconstr Surg 101(4):964–968 discussion 969 – 70.CrossRefPubMed
22.
Zurück zum Zitat Al-Ghazal SK et al (2000) The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol 26(1):17 – 9CrossRefPubMed Al-Ghazal SK et al (2000) The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol 26(1):17 – 9CrossRefPubMed
23.
Zurück zum Zitat Casey WJ et al (2010) Safety and efficacy of perforator flap breast reconstruction with combined intraabdominal procedures. Ann Plast Surg 64(2):144 – 50CrossRefPubMed Casey WJ et al (2010) Safety and efficacy of perforator flap breast reconstruction with combined intraabdominal procedures. Ann Plast Surg 64(2):144 – 50CrossRefPubMed
24.
Zurück zum Zitat Voss SC, Sharp HC, Scott JR (1986) Abdominoplasty combined with gynecologic surgical procedures. Obstet Gynecol 67(2):181–185CrossRefPubMed Voss SC, Sharp HC, Scott JR (1986) Abdominoplasty combined with gynecologic surgical procedures. Obstet Gynecol 67(2):181–185CrossRefPubMed
25.
Zurück zum Zitat Shull BL, Verheyden CN (1988) Combined plastic and gynecological surgical procedures. Ann Plast Surg 20(6):552–557CrossRefPubMed Shull BL, Verheyden CN (1988) Combined plastic and gynecological surgical procedures. Ann Plast Surg 20(6):552–557CrossRefPubMed
26.
Zurück zum Zitat Kryger ZB, Dumanian GA, Howard MA (2007) Safety issues in combined gynecologic and plastic surgical procedures. Int J Gynaecol Obstet 99(3):257 – 63CrossRefPubMed Kryger ZB, Dumanian GA, Howard MA (2007) Safety issues in combined gynecologic and plastic surgical procedures. Int J Gynaecol Obstet 99(3):257 – 63CrossRefPubMed
27.
Zurück zum Zitat Ma IT et al (2017) Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery. Ann Surg Oncol 24(1):77–83CrossRefPubMed Ma IT et al (2017) Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery. Ann Surg Oncol 24(1):77–83CrossRefPubMed
28.
Zurück zum Zitat Willsher P, Ali A, Jackson L (2008) Laparoscopic oophorectomy in the management of breast disease. ANZ J Surg 78(8):670–672CrossRefPubMed Willsher P, Ali A, Jackson L (2008) Laparoscopic oophorectomy in the management of breast disease. ANZ J Surg 78(8):670–672CrossRefPubMed
29.
Zurück zum Zitat Perabo M et al (2014) Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: a novel surgical approach to female BRCA-mutation carriers. Arch Gynecol Obstet 289(6):1325–1330PubMed Perabo M et al (2014) Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: a novel surgical approach to female BRCA-mutation carriers. Arch Gynecol Obstet 289(6):1325–1330PubMed
30.
Zurück zum Zitat Garvey EM et al (2013) Neoadjuvant therapy and breast cancer surgery: a closer look at postoperative complications. Am J Surg 206(6):894–898; discussion 898–9CrossRefPubMed Garvey EM et al (2013) Neoadjuvant therapy and breast cancer surgery: a closer look at postoperative complications. Am J Surg 206(6):894–898; discussion 898–9CrossRefPubMed
Metadaten
Titel
Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database
verfasst von
Maryam Elmi
Arash Azin
Ahmad Elnahas
David R. McCready
Tulin D. Cil
Publikationsdatum
14.05.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4818-7

Neu im Fachgebiet Onkologie

Neue chemotherapiefreie Kombinationstherapie punktet bei CLL

Zwischenergebnisse der Phase-III-Studie AMPLIFY sprechen dafür, dass die zeitlich begrenzte Behandlung mit Acalabrutinib und Venetoclax fitte Personen mit chronischer lymphatischer Leukämie länger leben lässt als eine Chemoimmuntherapie.

Ab sofort gelten die neuen Verordnungsausnahmen für Lipidsenker

Freie Fahrt für Lipidsenker? Das nicht, doch mit niedrigerem Schwellenwert fürs Infarktrisiko und neuen Indikationen hat der G-BA die Verordnungs-Handbremse ein gutes Stück weit gelockert.

NRG1-Fusionen als neues, klinisch relevantes Target

Ergebnisse einer Phase-II-Studie deuten darauf hin, dass ein gegen HER3 und HER2 gerichteter Antikörper bei verschiedenen NRG1-Fusions-positiven Tumoren wirksam sein könnte. In den USA ist die Substanz bereits beschleunigt zugelassen worden.

Die aktuelle S3-Leitlinie zu CLL strotzt vor Neuerungen

Vor kurzem wurde eine neue, grundlegend überarbeite Version der S3-Leitlinie Chronische Lymphatische Leukämie (CLL) veröffentlicht.  Zu den wichtigsten Änderungen gehört, dass die Chemoimmuntherapie auf dem Rückzug ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.